Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of remimazolam guided by EEG monitoring on perioperative hemodynamics and postoperative delirium in frail elderly patients
ChiCTR2300068172Phase 4Not yet recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in postoperative delirium (POD) and Fragility (2 arms), sponsored by Xuzhou Central Hospital. Primary endpoints: Incidence of postoperative delirium and Change of perioperative hemodynamics. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
postoperative delirium (POD)Fragility
Beyond the preview
Go deeper on ChiCTR2300068172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068172.